Baricitinib

Baricitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023 …
The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral ... [...]
2
Like
Save
Rheumatoid arthritis RA-BEACON illuminates baricitinib
Baricitinib therapy has demonstrated clinical efficacy in patients with rheumatoid arthritis (RA), according to the results of the RA-BEACON phase 3 trial just published in the New England Journal of Medicine. “Baricitinib works well in patients who ... [...]
3
Like
Save
Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis
We remind investors that in 2009, Incyte and Lilly had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize baricitinib and certain follow-on compounds, for the treatment of patients with inflammatory and ... [...]
5
Like
Save
Eli Lilly files oral rheumatoid arthritis drug baricitinib in US
Eli Lilly has filed its highly-anticipated rheumatoid arthritis treatment baricitinib in the US, setting the clock ticking on a possible approval later this year. The orally-active drug is considered a blockbuster contender on the back of clinical ... [...]
6
Like
Save
Lilly seeks US FDA approval for oral once-daily RA drug, baricitinib
... biopharmaceutical company, announced that Lilly has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid ... [...]
5
Like
Save
New Drug Application Submitted for Once-Daily Baricitinib for RA Patients
A new drug application (NDA) has been submitted to the FDA for the approval of oral once-daily baricitinib (Eli Lilly/Incite Corporation) for the treatment of moderately to severely active rheumatoid arthritis (RA). Baricitinib is the only once-daily ... [...]
7
Like
Save